article Closed Access EN 2015-03-01

[Significance of glucagon control in the diabetes treatment].

Tadahiro Kitamura

PubMed, Vol. 73, Issue 3, pp. 509–16 (2015)

PMID: 25812382
Google Scholar

Abstract

Among islet cell types, much less attention has been paid to α cells than to β cells, but glucagon, the product of α cells, has been shown to play a major role in the development of hyperglycemia in T2DM. Recent clinical application of DPP4 inhibitor and GLP-1 receptor agonist gave attention to glucagon again. Furthermore, recently metformin has been also reported to suppress glucagon's function on hepatic glucose production. One of the critical issues in the glucagon research is the poor specificity of current assay systems. Our newly developed glucagon sandwich ELISA, having higher specificity than conventional systems, revealed that T2DM patients have more severe hyperglucagonemia than currently assumed. Thus, in the future diabetes treatment, we should pay more attention to plasma glucagon levels in diabetes patients.

Topics

Diabetes Treatment and Management 0.99 Diabetes Management and Research 0.97 Diabetes and associated disorders 0.96

Field: Medicine · Subfield: Endocrinology, Diabetes and Metabolism

Keywords

Hyperglucagonemia,Glucagon,Diabetes mellitus,Medicine,Internal medicine,Endocrinology,Metformin,Islet,Glucagon receptor,Type 2 diabetes

MeSH Terms

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 2Diabetes Mellitus, Type 2Diabetes Mellitus, Type 2Diabetes Mellitus, Type 2Diabetes Mellitus, Type 2GlucagonGlucagon

UN Sustainable Development Goals

  • Good health and well-being (0.76)

All Available Versions

Continue on JournalsHub

Put what you just read into practice with these free tools.

Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now
Compare 0 Open → Clear
Save your viewing history
You've browsed several journals this session. Sign in to track them in one place and get weekly impact-factor updates.
Save with Google